Related Experiment Video
Updated: Dec 29, 2025
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Diagnostic Value of Peripheral Blood miR-374b-5p in Patients with Prostate Cancer
Background:
Increased evidence suggested the important role of microRNAs (miRNAs) in the tumorigenesis of prostate cancer (PCa). The aberrant expression of miRNA (miR)-374b-5p has been observed in various types of cancers. The purpose of the current study was to evaluate the relationship between miR-374b-5p expression levels and PCa and to assess the feasibility of using peripheral blood miR-374b-5p as a potential non-invasive biomarker for PCa.
Methods:
Total RNA was isolated from the whole-blood samples of 42 PCa patients whole-blood samples, 42 benign prostatic hyperplasia (BPH) patients, and 42 healthy controls (HC). The expression of miR-374b-5p was assessed by reverse transcription quantitative polymerase chain reaction. Normalized data were subjected to the receiver operating characteristic (ROC) and Kaplan-Meier analysis.
Results:
The expression of peripheral blood miR-374b-5p was significantly higher in PCa patients than in HC individuals and patients with BPH (p < 0.001). Upregulation of miR-374b-5p was observed to be related to certain parameters, including Gleason score > 7 (p < 0.001), and PSA > 20 ng/mL (p < 0.01). To further evaluate the role of miR-374b-5p in patients with PCa, ROC analysis was carried out. Our data showed that peripheral blood miR-374b-5p could screen PCa patients from HC individuals (area under the curve (AUC), 0.851; 95% CI, 0.766 - 0.936; p < 0.001) and patients with BPH (AUC, 0.831; 95% CI, 0.742 - 0.920; p < 0.001).
Conclusions:
Increased miR-374b-5p expression in peripheral blood may serve as a potential biomarker to distinguish PCa patients from healthy controls and BPH patients.
Insights
Elevated levels of microRNA (miR)-374b-5p in blood may help detect prostate cancer (PCa). This finding suggests miR-374b-5p could be a promising non-invasive biomarker for PCa diagnosis.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- MicroRNAs (miRNAs) play a crucial role in prostate cancer (PCa) tumorigenesis.
- Aberrant expression of miR-374b-5p is implicated in various cancers.
- Peripheral blood miR-374b-5p is explored as a potential non-invasive biomarker for PCa.
Purpose of the Study:
- To investigate the association between miR-374b-5p expression levels and PCa.
- To evaluate the utility of peripheral blood miR-374b-5p as a non-invasive biomarker for PCa detection.
Main Methods:
- Quantitative real-time PCR was used to measure miR-374b-5p expression in whole-blood samples.
- Samples were collected from 42 PCa patients, 42 benign prostatic hyperplasia (BPH) patients, and 42 healthy controls (HC).
- Receiver operating characteristic (ROC) and Kaplan-Meier analyses were performed on normalized data.
Main Results:
- Peripheral blood miR-374b-5p levels were significantly higher in PCa patients compared to HC and BPH groups (p < 0.001).
- Upregulation of miR-374b-5p correlated with higher Gleason scores (>7) and PSA levels (>20 ng/mL).
- ROC analysis demonstrated miR-374b-5p's ability to differentiate PCa from HC (AUC=0.851) and BPH (AUC=0.831).
Conclusions:
- Increased miR-374b-5p expression in peripheral blood shows potential as a biomarker.
- This biomarker can help distinguish PCa patients from healthy individuals and those with BPH.
- Peripheral blood miR-374b-5p offers a promising avenue for non-invasive PCa screening.
